Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum

Rhea-AI Summary

Simulations Plus (Nasdaq: SLP), a leader in biosimulation and medical communications for the biopharma industry, announced CEO Shawn O’Connor's participation in KeyBanc Capital Markets’ 25th Annual Technology Leadership Forum on August 5, 2024, in Vail, Colorado. O’Connor will host one-on-one meetings and participate in a panel discussion titled ‘AI and Digital Solutions for Drug Discovery’ before engaging in a 25-minute Fireside Chat at 1:30 p.m. MDT (3:30 p.m. EDT). A live audio webcast of the Fireside Chat will be accessible via a provided link and on the Investors page of the Simulations Plus website, where it will be available for replay for 90 days.

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will attend KeyBanc Capital Markets’ 25^th Annual Technology Leadership Forum on Monday, August 5, 2024, in Vail, Colorado. In addition to hosting one-on-one meetings throughout the day, Mr. O’Connor will join a panel discussion entitled “AI and Digital Solutions for Drug Discovery” followed by a 25-minute Fireside Chat at 1:30 p.m. MDT (3:30 p.m. EDT).

The live audio webcast of Mr. O’Connor’s Fireside Chat can be accessed via this link and also on the Investors page of the Simulations Plus website where the replay will be available for 90 days following the event.

About Simulations Plus

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240725922663/en/

Simulations Plus Investor Relations

Renee Bouche

661-723-7723

renee.bouche@simulations-plus.com

Financial Profiles

Lisa Fortuna

310-622-8251

slp@finprofiles.com

Source: Simulations Plus, Inc.

FAQ

When will Simulations Plus participate in KeyBanc's Technology Leadership Forum?

Simulations Plus will participate on August 5, 2024.

What is the stock symbol for Simulations Plus?

The stock symbol for Simulations Plus is SLP.

Who is representing Simulations Plus at KeyBanc's Technology Leadership Forum?

CEO Shawn O’Connor will represent Simulations Plus.

What topics will be discussed by Simulations Plus at the KeyBanc Technology Leadership Forum?

Discussions will include 'AI and Digital Solutions for Drug Discovery.'

How can I access the live webcast of Simulations Plus's participation in KeyBanc's forum?

The live audio webcast will be available via a provided link and on the Investors page of the Simulations Plus website.

Will there be a replay available for the Fireside Chat with Simulations Plus's CEO?

Yes, the replay will be available for 90 days following the event.